Literature DB >> 9701470

Osteoprogenitor cells in cell populations derived from mouse and rat calvaria differ in their response to corticosterone, cortisol, and cortisone.

C G Bellows1, A Ciaccia, J N Heersche.   

Abstract

Osteoprogenitors present in cell populations derived from fetal or newborn rat and mouse calvaria differentiate in long term culture and form osteoblastic bone-forming colonies (bone nodules). Previous reports have indicated considerable differences between bone cell populations derived from these two species with regard to their proliferation in response to glucocorticoids. In the present investigation, we have focused on proliferation and differentiation of osteoprogenitor cells in these bone cell populations and evaluated the effect of corticosterone, the principal glucocorticoid of both mouse and rat. Cells were isolated by sequential collagenase digestion from calvaria of newborn (2-5 days) CD-1 mice [mouse calvariae (MC) cells] and term fetal Wistar rats [rat calvaria (RC) cells] and cultured for up to 25 days in alpha-minimal essential medium containing 10% fetal bovine serum (FBS), antibiotics, 50 microg/mL ascorbic acid, and 8-10 mmol/L beta-glycerophosphate. In agreement with previous observations by us and others, corticosterone increased cell growth in RC cell cultures, but inhibited cell growth in MC cultures. In RC cell cultures, corticosterone (1-1000 nmol/L) increased the nodule number in a dose-dependent manner (p < 0.001 for all concentrations above 3 nmol/L) with a maximal effect at 300 and 1000 nmol/L (threefold increase over control). In MC cells, on the other hand, corticosterone (0.3-1000 nmol/L) increased the nodule number only at 30 nmol/L (50%, p < 0.01) but inhibited nodule formation by 33% (p < 0.001) at 1000 nmol/L. In both RC and MC cultures a linear relationship was found between the number of cells plated and number of nodules formed. When cultures were treated with cortisol (30-300 nmol/L), similar effects were observed; the number of nodules dose dependently increased in RC cell cultures and dose dependently decreased in MC cell cultures. Significantly, however, the inactive glucocorticoid cortisone also increased bone nodule formation in RC cell cultures and decreased bone nodule formation in MC cell cultures. Carbenoxolone, which blocks 11 beta hydroxysteroid dehydrogenase and thus prevents conversion of cortisone to cortisol, partially inhibited the cortisone-induced effects on bone nodule formation in both RC and MC cell cultures, indicating that both RC and MC cells can convert inactive glucocorticoids to active metabolites. In conclusion, our results show that the glucocorticoids corticosterone and cortisol inhibit proliferation and differentiation of osteoprogenitors in MC cell cultures but stimulate these processes in rat-derived osteoprogenitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9701470     DOI: 10.1016/s8756-3282(98)00084-2

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  11 in total

1.  The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization.

Authors:  W-K Suh; S X Wang; A H Jheon; L Moreno; S K Yoshinaga; B Ganss; J Sodek; M D Grynpas; T W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-18       Impact factor: 11.205

2.  ANA deficiency enhances bone morphogenetic protein-induced ectopic bone formation via transcriptional events.

Authors:  Kentaro Miyai; Mitsuhiro Yoneda; Urara Hasegawa; Sayaka Toita; Yayoi Izu; Hiroaki Hemmi; Tadayoshi Hayata; Yoichi Ezura; Shuki Mizutani; Kohei Miyazono; Kazunari Akiyoshi; Tadashi Yamamoto; Masaki Noda
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

3.  A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells.

Authors:  Xingming Shi; Weibin Shi; Qingnan Li; Buer Song; Mei Wan; Shuting Bai; Xu Cao
Journal:  EMBO Rep       Date:  2003-03-14       Impact factor: 8.807

4.  Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase 1 double-deficient mice.

Authors:  H Clarke Anderson; Dympna Harmey; Nancy P Camacho; Rama Garimella; Joseph B Sipe; Sarah Tague; Xiaohong Bi; Kristen Johnson; Robert Terkeltaub; José Luis Millán
Journal:  Am J Pathol       Date:  2005-06       Impact factor: 4.307

5.  Bone morphogenetic protein regulation of early osteoblast genes in human marrow stromal cells is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling.

Authors:  Anna M Osyczka; Phoebe S Leboy
Journal:  Endocrinology       Date:  2005-05-19       Impact factor: 4.736

6.  Haploinsufficiency of Runx2 results in bone formation decrease and different BSP expression pattern changes in two transgenic mouse models.

Authors:  Qisheng Tu; Jin Zhang; Jeff Paz; Katherine Wade; Pishan Yang; Jake Chen
Journal:  J Cell Physiol       Date:  2008-10       Impact factor: 6.384

7.  Inhibition of Wnt/β-catenin signaling by dexamethasone promotes adipocyte differentiation in mesenchymal progenitor cells, ROB-C26.

Authors:  Masako Naito; Kazuki Omoteyama; Yoshikazu Mikami; Tomihisa Takahashi; Minoru Takagi
Journal:  Histochem Cell Biol       Date:  2012-08-11       Impact factor: 4.304

8.  Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.

Authors:  Paloma Valverde; Jin Zhang; Amanda Fix; Ji Zhu; Wenli Ma; Qisheng Tu; Jake Chen
Journal:  J Bone Miner Res       Date:  2008-11       Impact factor: 6.741

9.  Regulation of BMP-induced transcription in cultured human bone marrow stromal cells.

Authors:  David L Diefenderfer; Anna M Osyczka; Jonathan P Garino; Phoebe S Leboy
Journal:  J Bone Joint Surg Am       Date:  2003       Impact factor: 5.284

10.  Osteogenic potential of osteoblasts from neonatal rats born to mothers treated with caffeine throughout pregnancy.

Authors:  Amanda Maria Sena Reis; Lorena Gabriela Rocha Ribeiro; Natália de Melo Ocarino; Alfredo Miranda Goes; Rogéria Serakides
Journal:  BMC Musculoskelet Disord       Date:  2015-02-04       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.